Cytosorbents Corporation CTSO
$5.75
$0.020.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.22M | 37.20M | 37.06M | 36.98M | 36.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.22M | 37.20M | 37.06M | 36.98M | 36.11M |
| Cost of Revenue | 10.57M | 10.79M | 10.57M | 11.04M | 11.58M |
| Gross Profit | 26.65M | 26.41M | 26.49M | 25.94M | 24.53M |
| SG&A Expenses | 34.14M | 35.34M | 35.62M | 33.96M | 33.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.34M | 50.57M | 51.28M | 50.85M | 52.05M |
| Operating Income | -12.13M | -13.37M | -14.22M | -13.87M | -15.94M |
| Income Before Tax | -18.61M | -12.25M | -8.60M | -12.36M | -11.56M |
| Income Tax Expenses | -401.00K | -401.00K | -401.00K | -2.09M | -1.69M |
| Earnings from Continuing Operations | -18.21 | -11.85 | -8.20 | -10.27 | -9.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.21M | -11.85M | -8.20M | -10.27M | -9.87M |
| EBIT | -12.13M | -13.37M | -14.22M | -13.87M | -15.94M |
| EBITDA | -10.70M | -11.90M | -12.72M | -12.35M | -14.40M |
| EPS Basic | -5.80 | -3.77 | -2.63 | -3.64 | -3.65 |
| Normalized Basic EPS | -3.44 | -2.22 | -1.50 | -2.70 | -2.64 |
| EPS Diluted | -5.80 | -3.80 | -2.65 | -3.66 | -3.67 |
| Normalized Diluted EPS | -3.44 | -2.25 | -1.53 | -2.72 | -2.66 |
| Average Basic Shares Outstanding | 12.56M | 12.55M | 12.44M | 12.04M | 11.63M |
| Average Diluted Shares Outstanding | 12.56M | 12.77M | 12.67M | 12.27M | 11.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |